BACKGROUND The PARTNER RCT demonstrated that TAVR with the Edwards Sapien valve (Edwards Lifesciences,
STUDY DEVICE AND PROCEDURE. The TF-TAVR procedure has been previously described (7) . In the randomized trial and the NRCA registry, a 22-F sheath was inserted for a 23-mm Edwards Sapien valve (Edwards Lifesciences, Irvine, California) and a 24-F sheath for a 26-mm valve. In the majority (>85%) of patients in the randomized trial, the valve was delivered with the RetroFlex 1 or 2 delivery systems (Edwards Lifesciences), whereas in the NRCA registry, the RetroFlex 3 delivery system was used for all patients (8, 9) . The RetroFlex 3 system allowed for easier crossing of the native valve due to changes in the nose cone of the delivery system and for more Fearon et al. The baseline characteristics of the 2 groups are displayed in Table 1 . The NRCA group was older, but had a lower STS score and logistic Euro-SCORE (European System for Cardiac Operative Risk Evaluation). A greater percent had received a Figure 2 .
The 30-day outcomes are displayed in Table 3 . Figure 3 .
DISCUSSION
The main finding in this study is that outcomes in the NRCA registry, including over 1,000 consecutive TF-TAVR patients were equivalent or superior to those of the RCT. In particular, major vascular and bleeding complications at 30 days were significantly lower in the NRCA cohort. The 1-year mortality in the NRCA group was significantly lower than in the RCT population (19.0% vs. 25.3%, p ¼ 0.009), whereas rates of neurologic events trended lower.
There are a number of factors that might contribute to the improved outcomes in the NRCA group.
Although this group was significantly older, fewer patients had cerebrovascular disease, peripheral arterial disease, renal disease, or oxygen-dependent chronic obstructive pulmonary disease; the mean STS and mean logistic EuroSCORE in the NRCA registry patients were significantly lower. These differences in baseline characteristics may be explained in part by improved patient selection as a result of Values are % or median AE SD.
Abbreviations as in Table 1 . Values are mean AE SD or n/N (%).
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; NRCA ¼ Nonrandomized Continued Access registry; PCI ¼ percutaneous coronary intervention; RCT ¼ randomized controlled trial; TAVR ¼ transcatheter aortic valve replacement; TF ¼ transfemoral.
Fearon et al.
investigator experience and in part by increased availability of the transapical access approach in the NRCA group (11) . These factors likely contributed to the dramatic reduction in vascular and bleeding complications, both of which decreased by >50%, and likely translated into the significant reduction in 1-year mortality seen in the NRCA patients (12, 13) .
Another important finding in this study is that with increased experience, procedural times and outcomes improved. In the RCT, the mean number of patients treated per site was only 15, whereas in the NRCA portion, it increased to 38 patients per Values are n (%).
Abbreviations as in Table 1 . 
CONCLUSIONS
In the NRCA registry of the PARTNER trial, which included over 1,000 patients undergoing TF-TAVR, procedural complications and 1-year outcomes, including death, were significantly reduced compared with those of the RCT. The improved results may reflect superior patient selection, advances in device technology, and enhanced procedural skills.
